Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21100933 | 0.88 | LTA4H (0.48) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL19934909 | 0.88 | FUCA1 (0.55) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL23054258 | 0.86 | S1PR5 (0.57) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL10859364 | 0.85 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL19604406 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL24970558 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL16228724 | 0.85 | NPC1 (0.53) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL21397345 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL23734315 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 | |
| SCHEMBL21440361 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| WO-2019023575-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-10174035-B2 | 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180072732-A1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ALDH1A1 104/4885MAPK1 3159/4885L3MBTL1 2864/4885 |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885MAPK1 2017/4885L3MBTL1 1394/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | ALDH1A1 3804/4885MAPK1 3144/4885L3MBTL1 1412/4885 |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | ALDH1A1 2539/4885MAPK1 3542/4885L3MBTL1 480/4885 |
| US-10174035-B2 | 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors | PIK3CA, AKT3, AKT2 | ALDH1A1 2619/4885MAPK1 102/4885L3MBTL1 4036/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ALDH1A1 4528/4885MAPK1 769/4885L3MBTL1 1005/4885 |
| US-20180072732-A1 | 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | PIK3CA, AKT3, AKT2 | ALDH1A1 2619/4885MAPK1 102/4885L3MBTL1 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.